pharmaceuticals
pharmaceuticals Articles
Bio Blast Pharma was blowing away all the other bulls in Wednesday’s session, with its stock up over 150% on positive clinical results.
Published:
Last Updated:
Shares of Cerus dropped just after the open of Wednesday’s regular trading session despite a key FDA approval.
Published:
Last Updated:
CEO Michael Pearson needs to leave Valeant Pharmaceuticals for it to have any chance to recover. The company cannot afford to keep him.
Published:
Last Updated:
Celator Pharmaceuticals has announced positive results from its Phase 3 trial of Vyxeos Liposome for Injection in patients with high-risk (secondary) acute myeloid leukemia.
Published:
Last Updated:
Aeglea BioTherapeutics has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
One analyst firm believes the development of abuse-deterrent formulations (ADF) of opioids creates a risk that older non-ADFs may be removed from the market, creating a huge risk and opportunity in...
Published:
Last Updated:
Valeant Pharmaceuticals International reported mixed preliminary fourth-quarter financial results before the markets opened on Tuesday.
Published:
Last Updated:
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.
Published:
Last Updated:
Vericel Corp. (NASDAQ: VCEL) reported its fourth-quarter financial results before the markets opened on Monday. The company said it had a net loss of $0.28 per share on $15.4 million in revenue,...
Published:
Last Updated:
Valeant Pharmaceuticals is scheduled to report its fourth-quarter preliminary results and update its 2016 financial guidance in a conference call Tuesday morning.
Published:
Last Updated:
GW Pharmaceuticals has announced the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex for the treatment of Dravet syndrome.
Published:
Last Updated:
24/7 Wall St. has collected three big FDA decisions coming up in March and added some color, along with the trading range and price target.
Published:
Last Updated:
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) scored a win in a late-stage trial for the treatment of rheumatoid arthritis (RA). The company, in conjunction with Sanofi, announced that a Phase 3...
Published:
Last Updated:
Corvus Pharmaceuticals expects to price more than 4 million shares in the range of $15 to $17 apiece in an initial public offering valued up to nearly $92 million.
Published:
Last Updated:
Audentes Therapeutics has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated: